Phaseline

Companies › Hutchmed

Hutchmed: clinical trials, targets and expected readouts

11 active drug programs in 38 registered trials: 24 Phase 2, 8 Phase 1, 5 Phase 3, 1 Phase 4; Oncology, Hematology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HMPL-306
IDH1/IDH2 inhibitor
IDH1, IDH2Phase 3Acute Myeloid Leukemia; Gliomas Harboring IDH1 and/or IDH2 MutationsDec 2026
HMPL-760
TBK1 inhibitor
–Phase 3Relapsed/Refractory Diffuse Large B-Cell LymphomaApr 2028
fruquintinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Advanced Endometrial Cancer; Advanced Renal Cell CarcinomaJan 2029
sintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Advanced Endometrial Cancer; Advanced Renal Cell CarcinomaJan 2029
Sovleplenib (HMPL-523)
Tyrosine-protein kinase SYK inhibitor
SYKPhase 2Warm Antibody Autoimmune Hemolytic AnemiaNov 2026
Surufatinib
Fibroblast growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor
FGFR1, FLT1, FLT4, KDRPhase 2Metastatic Pancreatic Cancer; Neuroendocrine Tumors; Pancreatic Cancer, Adult; Intrahepatic Cholangiocarcinoma …May 2028
Hmpl-453 (HMPL-453)
Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor
FGFR1, FGFR2, FGFR3Phase 2Advanced Intrahepatic CholangiocarcinomaJun 2028
HMPL-506–Phase 1Hematological MalignanciesOct 2027
HMPL-A251
HER2-targeting antibody-drug conjugate
–Phase 1Solid Tumors, AdultNov 2028
HMPL-A580–Phase 1Solid Tumors, AdultDec 2028
HMPL-A830–Phase 1Solid Tumor, AdultMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05218889SurufatinibPhase 1Pancreatic CancerOncologyDec 2024
NCT06239532SurufatinibPhase 2Intrahepatic CholangiocarcinomaOncologyDec 2024
NCT05165407SurufatinibPhase 2Neuroendocrine NeoplasmOncologySep 2025
NCT05522231fruquintinibPhase 2Advanced Renal Cell CarcinomaOncologyAug 2026
NCT05522231sintilimabPhase 2Advanced Renal Cell CarcinomaOncologyAug 2026
NCT05535933Sovleplenib (HMPL-523)Phase 2Warm Antibody Autoimmune Hemolytic AnemiaHematologyNov 2026
NCT05106777SurufatinibPhase 2SarcomaOncologyDec 2026
NCT07025018HMPL-306Phase 1Gliomas Harboring IDH1 and/or IDH2 MutationsOncologyDec 2026
NCT05969171SurufatinibPhase 2Pancreatic Cancer MetastaticOncologyDec 2026
NCT05481476SurufatinibPhase 2Pancreatic NeoplasmsOncologyDec 2026
NCT04922658SurufatinibPhase 2Advanced Non-Small Cell Lung CancerOncologyDec 2026
NCT05652283SurufatinibPhase 2Ovarian CancerOncologyMar 2027
NCT06708858SurufatinibPhase 2Advanced Biliary Tract CancerOncologyJul 2027
NCT05747729SurufatinibPhase 1Neuroendocrine CarcinomaOncologyJul 2027
NCT07357623SurufatinibPhase 2Pulmonary Neuroendocrine TumorOncologySep 2027
NCT06876844SurufatinibPhase 2Head and Neck CancerOncologySep 2027
NCT06387082HMPL-506Phase 1Hematological MalignanciesOncologyOct 2027
NCT05003037SurufatinibPhase 2Non Small Cell Lung CancerOncologyNov 2027
NCT07272512SurufatinibPhase 4Neuroendocrine TumorsOncologyNov 2027
NCT05472948SurufatinibPhase 2Adenocarcinoma of Small IntestineOncologyDec 2027
NCT07409428HMPL-760Phase 3Relapsed/Refractory Diffuse Large B-Cell LymphomaOncologyApr 2028
NCT06361888SurufatinibPhase 2Metastatic Pancreatic CancerOncologyMay 2028
NCT04353375Hmpl-453 (HMPL-453)Phase 2Advanced Intrahepatic CholangiocarcinomaOncologyJun 2028
NCT07436741SurufatinibPhase 3Pancreatic Cancer, AdultOncologySep 2028
NCT06719700SurufatinibPhase 2ToripalimabOncologyNov 2028
NCT07228247HMPL-A251Phase 1Solid Tumors, AdultOncologyNov 2028
NCT06387069HMPL-306Phase 3Acute Myeloid LeukemiaOncologyDec 2028
NCT07396584HMPL-A580Phase 1Solid Tumors, AdultOncologyDec 2028
NCT06584032fruquintinibPhase 3Advanced Endometrial CancerOncologyJan 2029
NCT06584032sintilimabPhase 3Advanced Endometrial CancerOncologyJan 2029
NCT07718581HMPL-A830Phase 1Solid Tumor, AdultOncologyMay 2029
NCT06447636SurufatinibPhase 2Gastric CancerOncologyMay 2029
NCT07609121SurufatinibPhase 2NSCLC (Non-small Cell Lung Cancer)OncologyMay 2029
NCT07086469SurufatinibPhase 2ToripalimabOncologyJul 2029
NCT07086456SurufatinibPhase 2SurufatinibOncologyJul 2029
NCT05839275SurufatinibPhase 1High-Risk Localized Soft Tissue SarcomaOncologyJul 2029
NCT07103395SurufatinibPhase 2Lung Cancer (NSCLC)OncologyDec 2029
NCT07505472SurufatinibPhase 2Rectal CancerOncologyDec 2029

From the company's SEC filings

Cash and short-term investments of $1.4bn on 2025-12-31; operating cash outflow about $65m a year; runway about 253 months at that burn, to Jan 2047; 6 of 6 coming phase 2-3 readouts fall inside that runway

Targets

FGFR1 (2) FLT1 (2) FLT4 (2) KDR (2) FGFR2 (1) FGFR3 (1) SYK (1) IDH1 (1) IDH2 (1) PDCD1 (1)

Companies with the same targets

Tyra Biosciences AstraZeneca Johnson & Johnson (Janssen) Exelixis Taiho Oncology QED Therapeutics, a BridgeBio company TransThera Sciences (Nanjing) Eisai Merck & Co. (MSD) Takeda

Companies built like this

Chipscreen Biosciences Nuvation Bio Ascentage Pharma Group Sellas Life Sciences Group Exelixis

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.